idebenone has been researched along with Cognition Disorders in 5 studies
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Noben (idebenone) was administered in dosage 120 mg during 6 months to 35 patients, aged from 60 to 86 years, with dementia, Alzheimer's type and mixed type, and with memory disturbances which did not reach the level of dementia." | 9.13 | [Noben (idebenone) in the treatment of dementia and memory impairment without dementia]. ( Meleshkov, MN; Voronkova, KV, 2008) |
| "Noben (idebenone) at a dose of 120 mg per day for six months was used in the treatment of 35 patients aged 60-86 years with Alzheimer's-type dementia, mixed dementia, and memory impairments not reaching the stage of dementia." | 7.75 | Use of Noben (idebenone) in the treatment of dementia and memory impairments without dementia. ( Meleshkov, MN; Voronkova, KV, 2009) |
| "Noben (idebenone) was administered in dosage 120 mg during 6 months to 35 patients, aged from 60 to 86 years, with dementia, Alzheimer's type and mixed type, and with memory disturbances which did not reach the level of dementia." | 5.13 | [Noben (idebenone) in the treatment of dementia and memory impairment without dementia]. ( Meleshkov, MN; Voronkova, KV, 2008) |
| "Noben (idebenone) at a dose of 120 mg per day for six months was used in the treatment of 35 patients aged 60-86 years with Alzheimer's-type dementia, mixed dementia, and memory impairments not reaching the stage of dementia." | 3.75 | Use of Noben (idebenone) in the treatment of dementia and memory impairments without dementia. ( Meleshkov, MN; Voronkova, KV, 2009) |
| "Primary outcome measures were the Alzheimer's Disease Assessment Scale-Cognitive Subcomponent (ADAS-Cog) and a Clinical Global Impression of Change (CGIC)." | 2.71 | Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. ( Berg, J; Ernstrom, K; Grundman, M; Margolin, R; Pfeiffer, E; Thal, LJ; Thomas, RG; Weiner, MF; Zamrini, E, 2003) |
| "Idebenone is a benzoquinone compound which has been investigated in elderly patients with dementia." | 2.39 | Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. ( Benefield, P; Gillis, JC; McTavish, D, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liao, C | 1 |
| Ashley, N | 1 |
| Diot, A | 1 |
| Morten, K | 1 |
| Phadwal, K | 1 |
| Williams, A | 1 |
| Fearnley, I | 1 |
| Rosser, L | 1 |
| Lowndes, J | 1 |
| Fratter, C | 1 |
| Ferguson, DJ | 1 |
| Vay, L | 1 |
| Quaghebeur, G | 1 |
| Moroni, I | 1 |
| Bianchi, S | 1 |
| Lamperti, C | 1 |
| Downes, SM | 1 |
| Sitarz, KS | 1 |
| Flannery, PJ | 1 |
| Carver, J | 1 |
| Dombi, E | 1 |
| East, D | 1 |
| Laura, M | 1 |
| Reilly, MM | 1 |
| Mortiboys, H | 1 |
| Prevo, R | 1 |
| Campanella, M | 1 |
| Daniels, MJ | 1 |
| Zeviani, M | 1 |
| Yu-Wai-Man, P | 1 |
| Simon, AK | 1 |
| Votruba, M | 1 |
| Poulton, J | 1 |
| Voronkova, KV | 2 |
| Meleshkov, MN | 2 |
| Thal, LJ | 1 |
| Grundman, M | 1 |
| Berg, J | 1 |
| Ernstrom, K | 1 |
| Margolin, R | 1 |
| Pfeiffer, E | 1 |
| Weiner, MF | 1 |
| Zamrini, E | 1 |
| Thomas, RG | 1 |
| Gillis, JC | 1 |
| Benefield, P | 1 |
| McTavish, D | 1 |
1 review available for idebenone and Cognition Disorders
| Article | Year |
|---|---|
Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders.
Topics: Administration, Oral; Aging; Benzoquinones; Cognition Disorders; Drug Administration Schedule; Human | 1994 |
2 trials available for idebenone and Cognition Disorders
| Article | Year |
|---|---|
Idebenone treatment fails to slow cognitive decline in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Benzoquinones; Cognition Disorders; Disease Progression; Double-Blind Metho | 2003 |
[Noben (idebenone) in the treatment of dementia and memory impairment without dementia].
Topics: Aged; Aged, 80 and over; Antioxidants; Attention; Cognition; Cognition Disorders; Dementia; Dose-Res | 2008 |
2 other studies available for idebenone and Cognition Disorders
| Article | Year |
|---|---|
Dysregulated mitophagy and mitochondrial organization in optic atrophy due to OPA1 mutations.
Topics: Antioxidants; Cells, Cultured; Cognition Disorders; DNA Mutational Analysis; DNA, Mitochondrial; Fam | 2017 |
Use of Noben (idebenone) in the treatment of dementia and memory impairments without dementia.
Topics: Aged; Aged, 80 and over; Antioxidants; Attention; Cognition; Cognition Disorders; Dementia; Dose-Res | 2009 |